Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)

NCT01117506 · View on ClinicalTrials.gov ↗

Study Summary

To validate the use of Corus CAD (Age/Sex/Gene Expression score - ASGES) blood assay in subjects who are referred for the work-up of coronary artery disease. The study will evaluate the clinical utility of a gene expression test Corus CAD (Age, Sex, Gene Expression Score - ASGES) in subjects referred for myocardial perfusion imaging (MPI) work-up for suspected obstructive atherosclerotic coronary artery disease (CAD). The Corus CAD (ASGES) is a gene expression test that quantify the expression of multiple genes from circulating peripheral blood cells to detect the presence of clinically significant obstructive CAD in patients with chest pain.

Interventions

  • DIAGNOSTIC_TEST Corus CAD (ASGES)

Study Locations (7)

California

  • Long Beach Memorial Hospital — Long Beach
  • Sutter Roseville Medical Center — Roseville

Colorado

  • Pikes Peak Cardiology — Boulder

Kansas

  • Midwest Cardiology Associates — Overland Park

Missouri

  • St. Luke's Hospital — Kansas City

Pennsylvania

  • Berks Cardiologists, Ltd — Wyomissing

Virginia

  • Cardiovascular Associates of Virginia — Midlothian

Trial Details

FieldValue
Enrollment Target 581 participants
Start Date 2010-04
Est. Completion 2012-05

Sponsor

CardioDx

3 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01117506

The ClinicalTrials.gov registry entry for NCT01117506 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 581 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CardioDx, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 8 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention — of which Corus CAD (ASGES) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01117506 reports 7 study locations spanning 6 distinct geographic areas — top geographies include California, Colorado, Kansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01117506 about?

NCT01117506 is a clinical study titled "Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)". To validate the use of Corus CAD (Age/Sex/Gene Expression score - ASGES) blood assay in subjects who are referred for the work-up of coronary artery disease. The study will evaluate the clinical utility of a gene expression test Corus CAD (Age, Sex, Gene Expression Score - ASGES) in subjects referre...

What is the current status of trial NCT01117506?

This trial is currently completed. The enrollment target is 581 participants. The study started on 2010-04. Estimated completion is 2012-05.

What conditions does trial NCT01117506 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Coronary Artery Disease, Chest Pain, Coronary Heart Disease, Angina Pectoris. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01117506?

The interventions under investigation include: Corus CAD (ASGES) (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01117506?

This trial is sponsored by CardioDx, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01117506 being conducted?

This trial has 7 study locations across California, Colorado, Kansas, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial